Herpes Simplex| A Drug Pipeline Analysis Report| Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest pipeline analysis report on the drug pipeline for herpes simplex. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat herpes simplex.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180910005811/en/

Technavio has published a new report on the drug development pipeline for the treatment of herpes simplex, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Herpes simplex: Market overview

Herpes simplex is a viral infection caused by herpes simplex virus (HSV). The virus can get transferred from one person to another through the point of contact. If a child encounters an HSV type-1 (HSV-1) infected adult, there are huge chances for the child to develop an infection.

According to a senior market research analyst at Technavio, “Herpes simplex can happen to anyone at any age, it is dependent on the amount a person is exposed to the infection. Once an individual is infected with the virus, this virus will live within the infected person throughout his or her life. There is a possibility that the virus may not show any symptoms, but it will keep on causing outbreaks sometimes regularly or occasionally. After the virus outbreaks for the first time, it becomes dormant, but still, it can trigger outbreak due to some stimuli in the infected person.”

Herpes simplex: Segmentation analysis

This pipeline analysis report segments the herpes simplex market based on therapies employed (monotherapy and combination therapy), RoA (oral, parenteral, topical, intradermal, intranasal, intramuscular, and subcutaneous), therapeutic modality (vaccine, small molecule, monoclonal antibody, and biological), targets (T-cell, B-cell and T-lymphocyte, DNA helicase-primase, HIV fusion, HSV helicase-primase, toll-like receptor 3), MoA (T-cell stimulator, B-cell and T-lymphocyte stimulator, DNA helicase-primase inhibitor, HIV fusion inhibitor, HSV helicase-primase inhibitor, toll-like receptor 3 inhibitor), geographical segmentation (US, Australia, Israel, Italy, Japan, and Taiwan) and recruitment status (active, not recruiting, completed, not applicable, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, around 43% of the molecules that are being investigated for the treatment of herpes simplex are vaccines.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

• Drugs under development
• Indications coverage

Drug Development Strategies

• Therapies employed
• RoA
• Therapeutic modality
• Geographical coverage

Recruitment Strategies

• Recruitment status
• Gender
• Age

Key Companies

• Type of players
• Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180910005811/en/